All Stories

  1. Sex-specific phenotypes and outcomes in non‑IPF interstitial lung disease: results from the INSIGHTS‑ILD registry
  2. Challenges in diagnosis of sarcoidosis
  3. Racial, Ethnic, Sex, and Gender Equity for Inclusive Interstitial Lung Disease Research: An Official American Thoracic Society Research Statement
  4. Sarcoidosis: A State-Of-The-Art Review
  5. Design of a Phase II randomised, double-blind, placebo-controlled, dose-finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosis
  6. Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
  7. Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
  8. Summary for clinicians: ERS guidelines on pulmonary alveolar proteinosis
  9. Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry
  10. The role of heat shock protein 90 in idiopathic pulmonary fibrosis: state of the art
  11. European Respiratory Society guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis
  12. Pathogenesis-driven treatment of primary pulmonary alveolar proteinosis
  13. Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
  14. Kidney manifestations of sarcoidosis
  15. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival
  16. Will inhalational GM-CSF replace whole lung lavage as a treatment for autoimmune pulmonary alveolar proteinosis? Many pole positions, not yet the final winner
  17. Pulmonale Alveolarproteinose (PAP)
  18. Pulmonale alveoläre Mikrolithiasis (PAM)
  19. Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
  20. Serum KL-6 as a Candidate Predictor of Outcome in Patients with SARS-CoV-2 Pneumonia
  21. Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
  22. Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
  23. MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis
  24. European Respiratory Society Statement on Familial Pulmonary Fibrosis
  25. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe
  26. Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective
  27. COVID-19 in patients with Pulmonary Alveolar Proteinosis A European multicenter study
  28. Genetic testing in interstitial lung disease: An international survey
  29. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
  30. Targeted therapy for pulmonary alveolar proteinosis: the time is now
  31. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
  32. Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?
  33. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden
  34. Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study
  35. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF
  36. Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting
  37. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF
  38. S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis
  39. Potential Clinical Utility of MUC5B und TOLLIP Single Nucleotide Polymorphisms (SNPs) in the Management of Patients with IPF
  40. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis
  41. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
  42. Ganzlungenlavage bei pulmonaler Alveolarproteinose – Schritt für Schritt
  43. Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception
  44. Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment
  45. When the Game Changes
  46. Hypersensitivity pneumonitis
  47. The perpetual enigma of bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: is it of diagnostic value?
  48. Looking into the future of sarcoidosis: what is next for treatment?
  49. Shedding light on developmental drugs for idiopathic pulmonary fibrosis
  50. Serum KL‐6 concentrations as a novel biomarker of severe COVID‐19
  51. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis
  52. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review
  53. Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis
  54. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis
  55. S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose
  56. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
  57. Genotype in MUC5B-Promoter Polymorphism and Chronic Lung Allograft Dysfunction (CLAD) in a German Cohort: Preliminary Results
  58. S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose
  59. Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose
  60. Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease
  61. Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study
  62. Therapie der systemischen Sklerose-assoziierten interstitiellen Lungenerkrankung
  63. Quantitative Lipidomics in Pulmonary Alveolar Proteinosis
  64. Shaping the future of an ultra-rare disease
  65. Editorial introductions
  66. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis
  67. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
  68. Correction to: The Burden of Sarcoidosis Symptoms from a Patient Perspective
  69. Pulmonary alveolar proteinosis
  70. The Burden of Sarcoidosis Symptoms from a Patient Perspective
  71. Changes in serum KL-6 levels are associated with the development of chronic lung allograft dysfunction in lung transplant recipients
  72. Erratum zu: Differenzialdiagnose interstitieller Lungenerkrankungen – „Interstitial pneumonia with autoimmune features“ (IPAF)
  73. Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia
  74. Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study
  75. Differenzialdiagnose interstitieller Lungenerkrankungen
  76. Die „Rheumalunge“ in der Computertomographie: radiologische Manifestationen der rheumatoiden Arthritis
  77. The Management of Patients With Idiopathic Pulmonary Fibrosis
  78. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey
  79. Patientenfragebogen zur Erfassung der Ursachen interstitieller und seltener Lungenerkrankungen – klinische Sektion der DGP
  80. Patients with IPF and lung cancer: diagnosis and management
  81. German Guideline for Idiopathic Pulmonary Fibrosis – Update on Pharmacological Therapies 2017
  82. Phenotypes of organ involvement in sarcoidosis
  83. Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies
  84. Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis
  85. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis
  86. Serum YKL-40 in workers at an indium-tin oxide production facility - Reply
  87. Idiopathic pleuroparenchymal fibroelastosis (PPFE) – A case study of a rare entity
  88. Therapeutic targets in idiopathic pulmonary fibrosis
  89. Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
  90. Differential diagnosis of granulomatous lung disease: clues and pitfalls
  91. Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis
  92. S2k-Leitlinie Idiopathische Lungenfibrose – Update zur medikamentösen Therapie 2017
  93. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis
  94. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone
  95. Coagulation factor XII regulates inflammatory responses in human lungs
  96. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis
  97. Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis
  98. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
  99. Deutschsprachige Validierung des „Kingʼs Brief Interstitial Lung Disease (K-BILD)“ Lebensqualitätsfragebogens für interstitielle Lungenerkrankungen
  100. New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis
  101. Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures
  102. Epidemiologie und klinisches Erscheinungsbild der Sarkoidose
  103. A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis
  104. European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity
  105. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis
  106. How to handle IPF – the new Portuguese consensus document
  107. An Important Step Forward, but Still a Way to Go
  108. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
  109. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
  110. Pulmonary alveolar proteinosis in a cat
  111. European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers
  112. Pulmonale Alveolarproteinose
  113. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
  114. New guideline on treatment of idiopathic pulmonary fibrosis
  115. GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders
  116. Positionspapier zur Bedeutung der forcierten Vitalkapazität für Patienten mit idiopathischer Lungenfibrose (IPF)
  117. Facts and promises on lung biomarkers in interstitial lung diseases
  118. Diagnosis of Sarcoidosis
  119. Update on therapeutic management of idiopathic pulmonary fibrosis
  120. Extracellular 20S proteasome in BAL and serum of patients with alveolar proteinosis
  121. MUC5Bpromoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis
  122. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
  123. Alveolar and intraparenchymal proteasome in sarcoidosis
  124. Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?
  125. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis
  126. Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease
  127. Interstitial lung disease
  128. Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPDgene polymorphisms
  129. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases
  130. The Ambitious Goal of Validating Prognostic Biomarkers for Systemic Sclerosis-related Interstitial Lung Disease
  131. Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia
  132. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose
  133. Sarkoidose
  134. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose
  135. Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis
  136. Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels
  137. Diagnostic approach to interstitial pneumonias in a single centre: report on 88 cases
  138. Hypersensitivity Pneumonitis
  139. Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis
  140. Chronic Hypersensitivity Pneumonitis
  141. KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndrome
  142. Self-reported asthma and respiratory symptoms among Italian amateur athletes
  143. Whole-Lung Lavage: A Successful Treatment for Restoring Acinar Ventilation Distribution in Primary Acquired Pulmonary Alveolar Proteinosis
  144. Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation
  145. Pulmonary alveolar proteinosis: New insights from a single-center cohort of 70 patients
  146. Therapie der Lungenfibrose
  147. Diagnostic Modalities in Sarcoidosis: BAL, EBUS, and PET
  148. A female soccer player with recurrent haemoptysis and iron deficiency anaemia: idiopathic pulmonary haemosiderosis (IPH)--case report and literature review
  149. Angiogenic and Angiostatic Chemokines in Idiopathic Pulmonary Fibrosis and Granulomatous Lung Disease
  150. To BAL or Not to BAL: Is This a Problem in Diagnosing IPF?
  151. Die bronchoalveoläre Lavage aus klinischer Sicht
  152. Significance of Bronchoalveolar Lavage for the Diagnosis of Idiopathic Pulmonary Fibrosis
  153. Acid reflux into the oesophagus does not influence exercise-induced airway narrowing in bronchial asthma
  154. Bronchoalveolar Lavage in Other Interstitial Lung Diseases
  155. Omeprazole reduces the response to capsaicin but not to methacholine in asthmatic patients with proximal reflux
  156. Biomarkers